MENU
+Compare
ICCC
Stock ticker: NASDAQ
AS OF
Oct 16, 04:15 PM (EDT)
Price
$6.42
Change
-$0.20 (-3.02%)
Capitalization
58.71M

ICCC stock forecast, quote, news & analysis

ImmuCell Corp is engaged in the healthcare sector... Show more

ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for ICCC with price predictions
Oct 15, 2025

ICCC in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 01, 2025

ICCC broke above its upper Bollinger Band on October 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In of the 38 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where ICCC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on October 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ICCC as a result. In of 122 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ICCC just turned positive on September 23, 2025. Looking at past instances where ICCC's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

ICCC moved above its 50-day moving average on October 01, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ICCC crossed bullishly above the 50-day moving average on October 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICCC advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 114 cases where ICCC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ICCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.966) is normal, around the industry mean (24.545). P/E Ratio (30.905) is within average values for comparable stocks, (55.406). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.185). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.015) is also within normal values, averaging (345.728).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.05B. The market cap for tickers in the group ranges from 58 to 104.58B. VRTX holds the highest valuation in this group at 104.58B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 81%. GNPX experienced the highest price growth at 243%, while CARM experienced the biggest fall at -87%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 128% and the average quarterly volume growth was 456%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 52
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of products for cattle health

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
56 Evergreen Drive
Phone
+1 207 878-2770
Employees
79
Web
https://www.immucell.com